Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disease that is characterized by an overproduction of immature myeloid cells and mature granulocytes. A reciprocal chromosome translocation t(9;22), called the Philadelphia chromosome, causes a constitutive activation of the BCR-ABL tyrosine kinase and leads to the development of CML (Deininger et al., 2000; Ren 2005) . For this reason, current CML treatment strategies involve the use of tyrosine kinase inhibitors such as 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (imatinib), nilotinib, and dasatinib (Sawyers, 2001; Kantarjian et al., 2006; Steinberg, 2007) . 4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-ylpyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide (flumatinib, HH-GV678), a structural analog of imatinib ( Fig. 1) , is currently undergoing Phase I clinical trials in China in oral form as its mesylate salt. Previous nonclinical studies have shown flumatinib to have more potent in vitro and in vivo activity than imatinib when tested against leukemia cells expressing BCR-ABL (Sun et al., 2008) . The current clinical trials are being performed to assess tolerability and pharmacokinetic properties of flumatinib, as well as to determine its initial therapeutic efficacy in CML patients.
The objective of the present study was to investigate the metabolism of flumatinib in CML patients using an ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC/Q-TOF MS) method. The metabolic profiles of flumatinib in plasma, urine, and feces were characterized after its oral administration to CML patients enrolled in the clinical study.
(St. Louis, MO). Purified water was generated by a Millipore (Molsheim, France) Milli-Q Gradient Water Purification System.
Subjects and Sample Collection. The study protocol was previously approved by the Ethics Committee of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. CML patients in accelerated phase or in the blast crisis phase, aged 18 to 65 years old, were enrolled in the tolerability and pharmacokinetic study. Plasma, urine, and feces samples before and after oral administration of flumatinib mesylate had been collected for the pharmacokinetic study. We used the remaining samples from this previous trial for the present metabolism studies. All the samples had been stored at Ϫ20°C until analysis.
Preparation of Plasma, Urine, and Feces Samples for Metabolite Analysis. Human plasma samples had been collected 3, 8, and 12 h postdose. Urine samples had been collected over a 0-to 12-h collection interval after administration. These collected samples were pooled to form a single plasma sample and a single urine sample. A 500-l aliquot of pooled sample was diluted with water of the same volume, and the mixture was vortexed and centrifuged at 5000g for 5 min (4°C). The supernatant was passed through an Oasis hydrophilic-lipophilic balance solid-phase extraction cartridge (1 ml, 30 mg; Waters, Milford, MA) preconditioned with 1 ml of methanol and 2 ml of water. The cartridge was washed with 1 ml of water and eluted with 2 ml of methanol. The eluate was evaporated to dryness under a stream of nitrogen gas at 40°C in a Turbo Vap evaporator (Zymark Corp., Hopkinton, MA). The residue was reconstituted in 150 l of water/acetonitrile/formic acid (90:10:0.05, v/v) and centrifuged at 16,000g for 5 min (4°C). A 10-l aliquot of the supernatant was injected into the UPLC/Q-TOF MS system.
A 20-mg feces sample was mixed with 2 ml of methanol and homogenized, then extracted by ultrasonication. After centrifugation at 16,000g for 15 min (4°C), the supernatant was evaporated to dryness under a stream of nitrogen gas at 40°C. The residue was reconstituted in 300 l of water/acetonitrile/ formic acid (90:10:0.05, v/v) and centrifuged at 16,000g for 5 min (4°C). A 2-l aliquot of the supernatant was injected into the UPLC/Q-TOF MS system.
To identify the N-oxides, the biological matrices were treated with a reductant titanium trichloride (TiCl 3 ), which can selectively reduce N-oxides to their corresponding amines (Seaton et al., 1984; Kulanthaivel et al., 2004) . TiCl 3 (5 l) was added to a 500-l aliquot of urine or a 2-ml aliquot of feces extraction. After 90 min at 0°C, they were treated as described before and analyzed.
UPLC and MS Apparatus. Chromatographic separation was performed using a Waters ACQUITY UPLC system equipped with a binary solvent delivery system, column oven, and autosampler. Mass spectrometry was performed on a SYNAPT Q-TOF MS (Waters) equipped with an electrospray ionization source (ESI). The raw data were acquired and processed by MassLynx version 4.1, MetaboLynx, and MassFragment software (Waters). An LCQ Advantage ion trap spectrometer (Thermo Fisher Scientific, Waltham, MA) equipped with an ESI was used for the fragmentation study.
UPLC Conditions. Chromatographic separations were achieved on an ACQUITY UPLC bridged ethyl hybrid column (2.1 ϫ 100 mm, 1.7 m; Waters) thermostated at 40°C. The autosampler was maintained at 10°C. The components were eluted with a gradient of formic acid (0.05%) in water (mobile phase A) versus formic acid (0.05%) in acetonitrile (mobile phase B) at a flow rate of 0.5 ml/min. The gradient elution program was 98% A at 0 min, 98 to 95% A at 0 to 4 min, 95 to 80% A at 4 to 22 min, 80 to 20% A at 22 to 24 min, 20 to 0% A at 24 to 26 min, and 0 to 98% A at 26 to 30 min. The system was equilibrated at 98% A for 4 min before the next run.
Q-TOF MS Conditions. Mass spectrometry was performed in the positive ion mode electrospray. The capillary and cone voltages were 1500 and 50 V, respectively. The desolvation gas (nitrogen) was set to 800 l/h at a temperature of 400°C, and the source temperature was 120°C. Data were acquired from 50 to 1000 Da and corrected during acquisition using an external reference (lock spray) composed of a solution of 600 ng/ml leucine enkephalin (m/z 556.2771) infused at 5 l/min. An MS E scan function was programmed with two independent collision energies (CEs). At low CE, the transfer CE and trap CE were 4 and 6 eV, respectively. At high CE, the transfer CE and trap CE were 4 eV and were ramped from 25 to 35 eV, respectively. In this manner, precursor ion and fragmentation information were obtained in one sample run (Bateman et al., 2007) .
LCQ Ion Trap MS Conditions. To elucidate the MS fragmentation pathways, MS n mass spectra were obtained in the ESI positive ion mode. Nitrogen was used as the sheath gas (35 arbitrary units). No auxiliary gas was used. The spray and capillary voltages were set at 4.5 kV and 30 V, respectively. The capillary temperature was set to 200°C. Samples were introduced into the MS by syringe pump. MS n mass spectra were obtained by collision-induced dissociation. The CE was adjusted to provide characteristic fragment ions of each precursor ion.
Flumatinib Metabolite Profiling in Patient Plasma, Urine, and Feces. For the metabolite identification of flumatinib, plasma, urine, and feces extracts were injected into the UPLC/Q-TOF MS system. Data acquisition and processing were performed using MS E with the mass defect filtering approach (Bateman et al., 2007; Zhang et al., 2008) . For each metabolite chromatographic peak found, its corresponding precursor and fragment ions were available from the mass spectra obtained at low and high CE, respectively. The elemental composition of each metabolite and its structure were analyzed by MetaboLynx software (Waters).
Results
Mass Spectral Fragmentation Study of Flumatinib. Flumatinib (100 ng/ml) was injected and analyzed using UPLC/MS E Q-TOF MS to obtain its mass spectral information at low and high CE. The mass spectrum of flumatinib at high CE is shown in Fig. 2 proposed mass spectral fragmentation patterns of flumatinib and imatinib are shown in Fig. 2 . The expected metabolite chromatograms for plasma, urine, and feces are shown in Fig. 3 .
Metabolite Characterization. 160.0, 151.9, 148.7, 148.0, 140.7, 137.2, 135.0, 134.2, 134.1, 134.0, 132.5, 132.2, 131.3, 127 .9 (q, J ϭ 30 Hz), 125.7 (q, J ϭ 5 Hz), 124.5 (q, J ϭ 273 Hz), 124.2, 124.0, 108.8, 57.0, 53.2 (2ϫC) , 49.9 (2ϫC), 42.6, and 21.2. The NMR data of flumatinib are shown in Supplemental Data Figs. S1 to S4.
Metabolite M1. Metabolite M1, found in plasma, urine, and feces, eluted at 19.1 min with a protonated molecular mass of 549.234. Its elemental composition was C 28 H 27 F 3 N 8 O. M1 was a demethylated form of the parent drug. The major fragment ions at m/z 463. 149, 449.134, 263.105, and 262.102 were the same as those of parent drug. Only m/z 100 was lacking, which indicated that the demethylation occurred on the methylpiperazine moiety. The chromatographic retention time and mass spectral fragmentation patterns of M1 were identical to the synthesized reference standard of N-desmethyl flumatinib; M1 was accordingly confirmed as the N-desmethyl flumatinib, which has been shown to have similar pharmacological properties as the parent drug. 
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Metabolite M2. Metabolite M2 had a protonated molecular mass of 579.244, which was 16 Da higher than the protonated parent drug. Its elemental composition was C 29 H 29 F 3 N 8 O 2 , indicating that an oxygen atom had been introduced into the molecule to form an N-oxidation or hydroxylation metabolite of M0. Up to 4, 7, and 9 chromatographic peaks with a protonated ion at m/z 579.244 were detected in extracts of plasma, urine, and feces, respectively. These oxides were numbered according to their order of chromatographic retention time, and the structures were elucidated by their mass spectral fragments. The chromatograms of human urine and feces reduced and unreduced by TiCl 3 are shown in Supplemental Data Figs. S13 and S14.
Metabolites M2-1 and M2-6 eluted at 16.2 and 18.5 min, respectively. The major fragment ion at m/z 479.146 showed the oxygen was introduced into part B (Fig. 4) . Treatment with TiCl 3 resulted in the disappearance of these two peaks, which suggested that M2-1 and M2-6 were N-oxides. Therefore, we proposed that an oxygen atom 
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at ASPET Journals on June 24, 2017 dmd.aspetjournals.org indicated the formation of a hydroxyl group on the parent drug moiety. Because the other major fragment ion at m/z 462.140 showed that part B was intact, we tentatively identified M2-8 as a metabolite hydroxylated at the methylpiperazine group. M2-8 eluted after M0 as a result of the formation of an intramolecular hydrogen bond between the hydroxyl hydrogen and hydrogen acceptor nitrogen, which led to the lower polarity of the moiety.
Metabolite M2-9, found in all three samples, eluted at 21.3 min. The primary fragment ion was m/z 464.160, which resulted from the formation of a radical ion by the loss of the methylpiperazine moiety, suggesting that part B was intact and that the oxygen atom was introduced into the methylpiperazine group. The mass spectral fragmentation patterns were similar to unchanged flumatinib, except for the appearance of fragment ions at m/z 492.178 and 116.052, which confirmed the oxidation of the methylpiperazine group. Treatment with TiCl 3 resulted in the disappearance of the peak corresponding to M2-9, which suggested that M2-9 was an N-oxide. The standard reference was synthesized chemically using m-chloroperoxybenzoic acid, and the reaction temperature was kept at Ϫ20°C. The NMR spectra data (including 1 H and 13 C) confirmed the proposed structure and provided the positional information of the oxygen atom. Fig. 4 .
Metabolite M3. Metabolite M3, found in plasma and urine, eluted at 11.0 min and had a protonated molecular mass of 303.132, with an elemental composition of C 14 H 17 F 3 N 2 O 2 . This metabolite was the most abundant metabolite in plasma and urine. A fragment ion at m/z 203.032 resulted from a neutral loss of the methylpiperazine moiety, which was similar to that of the parent drug. The primary fragment ion of protonated M3 was at m/z 175.037; its elemental composition was proposed to be C 8 H 6 F 3 O. To elucidate the mass fragmentation pathways, an MS n scan was performed on an LCQ Advantage ion trap spectrometer (Thermo Fisher Scientific). Figure 5 shows the MS to MS 5 mass spectra and the proposed mass spectral fragmentation routes of M3. By comparing the chromatographic retention time and mass spectrum with that of the synthesized reference standard, metabolite M3 was confirmed as the amide hydrolytic product of flumatinib that formed a carboxylic acid.
Metabolite M4. Metabolite M4, found in plasma and urine, eluted at 5.8 min and had a protonated molecular mass of 279.136, with an elemental composition of C 15 H 14 N 6 . The major mass spectral fragment ion at m/z 262.111 resulted from the neutral loss of the NH 3 moiety. Other major fragment ions at m/z 78.035, 156.058, 173.084, and 235.099 were produced from C-C, C-N bond cleavage or the cleavage across pyridine ring (see Fig. 6 ). By comparing its chromatographic retention time and mass spectrum with that of the synthesized reference standard, M4 was confirmed as the amide hydrolytic product of flumatinib that formed an amine. The standard compound was characterized as follows 161.4, 159.9, 151.8, 148.8, 143.4, 140.0, 134.8, 134.1, 132.6, 132.0, 124.3, 117.6, 108.2, and 20.3 . The NMR data of M4 are shown in Supplemental Data Figs. S9 and S10.
Metabolite M5. Metabolite M5, found in plasma and urine, eluted at 10.5 min and had a protonated molecular mass of 289.112 and a molecular formula of C 13 H 15 F 3 N 2 O 2 , indicating a demethylation (ϪCH 2 ) of M3. The major mass spectral fragment ions at m/z 203.033 and 175.037 were similar to those of M3 except for the disappearance of m/z 100, suggesting a modification on the methylpiperazine group. The minor fragment ion at m/z 85.078 further proved that M5 was the N-demethylation product of M3. Hence, M5 was proposed as the piperazine N-desmethyl metabolite of M3, and its structure was confirmed by comparison with the synthesized reference standard. A fragment ion at m/z 258.076 indicated the oxidation site to be the nitrogen atom connected with the methyl group (see Fig. 7 ).
Metabolite M7. Metabolite M7 eluted at 7.6 min in urine and gave a protonated ion at m/z 317.113 with a larger mass of 14 Da than M3, and its elemental composition was C 14 H 15 F 3 N 2 O 3 , indicating the introduction of an oxygen atom with dehydrogenation. Mass spectral fragment ions of M7 were similar to those of M6, and m/z 203.037 and 175.035 suggested that the modification occurred on the methylpiperazine moiety. A fragment ion at m/z 246.070 further indicated the methylpiperazine group underwent oxidation, but the position could not be confirmed. Metabolite M7 was tentatively identified as the oxidation product of M3 with carboxide formation (see Fig. 7 ).
Metabolites M8 and M9. Metabolites M8-1, M8-2, and M8-3 gave a precursor ion at m/z 295.131, which was 16 Da larger than that of metabolite M4. Their elemental composition was C 15 H 14 N 6 O, suggesting an oxidation metabolite of M4 (m/z 279.136, C 15 H 14 N 6 ). For M8-1, a fragment ion at m/z 278.118 resulted from a neutral loss of NH 3 , whereas m/z 105.053 was the same as that of M4, indicating that the pyridine group was intact, but the oxidation position could not be confirmed. M8-2 showed fragment ions at m/z 277.121, 263.106, and 262.108, which were identical to the parent drug, indicating that part A and the methyl group were intact. Hence, we concluded that the primary amine substituent group in M4 was hydroxylated. For M8-3, a fragment ion at m/z 277.121 resulted from a neutral loss of H 2 O, supposing the formation of hydroxyl group. The major fragment ions of m/z 250.110, 173.084, and 156.056 showed that the pyridinepyrimidine-amino group was intact. M8-3 was tentatively identified as a hydroxylation metabolite at methylpyridine moiety (see Fig. 6 ). Metabolite M9 gave a precursor ion at m/z 311.126, which was 32 Da larger than that of M4. Its elemental composition was C 15 H 14 N 6 O 2 , suggesting a dioxide of M4, but the structure could not be confirmed by the mass spectrum.
Metabolite M10. Metabolite M10, found in plasma and urine, eluted at 8.1 min with a precursor ion at m/z 321.148, which was 42 1332 GONG ET AL.
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Da larger than that of M4. Its elemental composition was C 17 H 16 N 6 O. The mass spectrum of M10 showed a major fragment ion at m/z 262.109, suggesting the modification occurred on the primary amine group. Metabolite M10 was identified as the acetylation metabolite of M4 on the primary amine substituent. The standard substance was synthesized chemically using acetic anhydride under room temperature. The chromatographic retention time and mass spectra of the standard substance were the same as that of M10. 1 H and 13 C NMR 170.6, 162.3, 160.8, 159.2, 150.5, 147.6, 146.1, 135.4, 134.6, 134.5, 134.2, 133.0, 124.0, 122.6, 108.3, 22.3, and 18.7 . The NMR data of M10 are shown in Supplemental Data Figs. S11 and S12. Metabolite M12. Metabolite M12, found in urine and feces, eluted at 22.7 min with a precursor ion at m/z 563.214. Its elemental composition was C 28 H 25 F 3 N 8 O 2 , indicating the demethylation, dehydrogenation, and oxidation of M0. In the mass spectrum, M12 showed one primary fragment ion at m/z 463.155, suggesting the methylpiperazine group was metabolized. M12 was identified as a carbonylation metabolite of M1 with lactam formation, but the exact position could not be confirmed by the mass spectrum.
Metabolite M13. Metabolite M13, found in urine and feces, eluted at 16.0 min with a precursor ion at m/z 565.225. The elemental composition of M13 was C 28 H 27 F 3 N 8 O 2 , indicating the demethylation and oxidation of M0. The fragment ion at m/z 547.226 was generated by a neutral loss of H 2 O. The primary mass spectral fragment ion of M13 was m/z 173.055, indicating that pyridinepyrimidine-amino group was intact. M13 was tentatively identified as the hydroxylation metabolite of M1, but the exact position could not be confirmed.
Metabolite M14. Metabolite M14, found in plasma and urine, eluted at 20.2 min with a protonated precursor ion at m/z 577.229. Its elemental composition was C 29 H 27 F 3 N 8 O 2 , indicating the introduction of an oxygen atom with dehydrogenation. The major fragment ion at m/z 463.150 showed that the modification occurred on the methylpiperazine group. M14 was tentatively identified as a metabolite with a lactam formation on the piperazine ring.
Metabolite M15. Metabolite 15-1, found in urine, eluted at 18.1 min, showing a protonated precursor ion at m/z 595.239, which was 32 Da larger than that of M0. The elemental composition of M15-1 was C 29 H 29 F 3 N 8 O 3 , indicating a dioxide of M0. The major fragment ions at m/z 492.170 and 463.150 suggested the oxidation was located on the methylpiperazine group. A fragment ion at m/z 577.232 with a high relative abundance was produced by a neutral loss of H 2 O, which indicated that a hydroxyl group was formed. M15-1 was identified as a dioxide of M0 on the methylpiperazine group. Metabolite M15-2 was eluted at 17.5 min in feces extracts, showing a protonated precursor ion at m/z 595.242, and its elemental composition was identical with M15-1. No obvious fragment ion was produced, and the oxidation site of M15-2 could not be confirmed.
Metabolite M16. Metabolites M16-1 and M16-2 were eluted at 11.8 and 18.5 min, respectively. Both showed a precursor ion at m/z 739.283, which was 176 Da larger than that of M0. Their mass spectra were identical, and the major fragment ion was at m/z 563.246, indicating that two glucuronide conjugates of the parent drug M0 were produced, but the conjugation sites could not be confirmed. Two chromatographic peaks with the same retention time as that of M16-1 and M16-2 could be detected in the extracted ion chromatogram of 8B ). Metabolite M17. Metabolite M17, found in urine, eluted at 11.7 min with a precursor ion at m/z 725.267. M17 showed a major fragment ion at m/z 549.241, indicating a neutral loss of 176 Da. It was supposed that M17 was a glucuronide conjugate of M1. Likewise, a chromatographic peak with the same retention time as M17 could be found in the extracted ion chromatogram of m/z 549.234 as a result of the in-source dissociation of M17 (see Fig. 8C ).
Metabolite M18. Metabolites M18-1, M18-2, and M18-3 showed a precursor ion at m/z 755.280 with a mass of 176 Da larger than m/z 579.244, indicating three glucuronide conjugates of flumatinib monooxide (M2). The mass spectra of M18-1 and M18-3 showed major fragment ions at m/z 479.145 and 279.096, 16 Da larger than m/z 463.148 and 263.105 of M0, respectively, suggesting that the oxidation site was on part A. The mass spectrum of M18-2 was similar to M2-1 and M2-6, indicating that part A was oxidized into an N-oxide. Three chromatographic peaks with the same retention time as those of M18-1, M18-2, and M18-3 could be detected in the extracted ion Fig. 8D ).
Discussion
The metabolism of flumatinib, a new tyrosine kinase inhibitor for treatment of CML, was studied by UPLC/Q-TOF MS analysis of plasma, urine, and feces of CML patients after oral administration during Phase I trials. The chemical structures of the metabolites were characterized by their accurate mass, mass spectral fragmentation patterns, and comparison with the chemically synthesized reference standards. The identified metabolic processes are shown in Fig. 9 .
After oral administration, flumatinib was extensively metabolized. Up to 13 metabolites were detected in plasma extracts. The most abundant drug-related component in plasma extract was the parent drug. In addition to the unmetabolized flumatinib, the primary metabolites in plasma were N-desmethyl flumatinib (M1), a metabolite with similar pharmacological properties to flumatinib, and the amide hydrolysis product M3. The content of M3 in plasma was approximately 30% of that of the parent drug, based on the peak area percentage. Some minor metabolites in plasma included oxidation metabolites (M2-1, M2-4, M2-7, M2-9, and M14) and a hydrolysis metabolite (M4), which were further metabolized to form multiple metabolic products (M5, M6, M8-3, and M10). Furthermore, one glucuronide conjugate of parent drug M16-2 was detected in plasma.
In addition to the parent drug, 30 metabolites were detected in urine. The primary metabolite in urine was the amide hydrolysis product M3, whose content was 3 times higher than that of unmetabolized parent drug. Other major metabolites included N-desmethyl flumatinib (M1), hydrolysis metabolite (M4), oxidation metabolites (M2-1 and M2-9) among others, which could be further metabolized into multiple metabolic products. Several phase II metabolites were also detected, including the glucuronide conjugates of M0, M1, M2, and M3 and the acetylation product of M4.
After oral administration, a large amount unmetabolized parent drug was detected in feces, which could be explained either by the excretion through bile or by poor oral absorption of flumatinib. In addition to the parent drug, N-desmethyl metabolite (M1), N-demethylation coupled with oxidation metabolites (M12 and M13), oxidation metabolites of M0 (M2-1-M2-9, and M15-2), and one acetylation metabolite of M1 (M20) were excreted.
The major drug-related components in circulation were the parent compound, N-desmethyl flumatinib (M1), and the amide hydrolytic metabolite (M3). M3 was the primary metabolite in both plasma and urine. Many metabolites related to hydrolysis metabolite M4 were detected in plasma and urine (i.e., M4, M8, M9, and M10), which suggested that the predominant metabolic pathway of flumatinib in humans was amide hydrolysis. The relatively low amounts of M4 and its metabolites, compared with the parallel hydrolytic product M3 and its metabolites, were proposed and that some of the metabolites related to M4 were probably missed out. The relationship of structure and metabolic pathways was analyzed, and we concluded that there were at least two possible causes leading to the amide hydrolysis. First, the introduction of the trifluoromethyl electron-withdrawing group enhances the electrophilicity of the amide carbon atom that may facilitate hydrolysis of the amide bond. Second, the change from a Table 1 .
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at ASPET Journals on June 24, 2017 dmd.aspetjournals.org phenyl ring in imatinib to a pyridine ring in flumatinib adds another electron-withdrawing group (Gschwind et al., 2005; Marull and Rochat, 2006) , and electron withdrawal would be enhanced by protonation of the pyridine moiety. Such protonation may also provide a site for either an ionic bridge or hydrogen bond with esterase/amidase active site, and thereby increase the affinity of flumatinib for the enzyme. Stability tests of flumatinib in phosphate buffer, pH 7.4, incubated at 37°C for 2 h and in plasma kept at room temperature for 2 h proved that flumatinib was stable and that no in vitro degradation occurred. Therefore, we concluded that the amide hydrolytic reaction occurred only in vivo.
During the progress of this Phase I clinical trial, the long-term toxicity tests of Sprague-Dawley rat, beagle dog, and cynomolgus monkey were assessed, and plasma samples for toxicokinetics studies were collected. The remaining samples were used for metabolite identification using the identical UPLC/Q-TOF MS method used for human samples. In the study, there were large amounts of the parent drug, M0, in the plasma of rat, dog, monkey, and human. The primary metabolites in circulation were similar in these four species, and metabolite M3 was the most abundant metabolite, especially in rat and dog with the peak areas more than 2 and 4 times that of M0, respectively. In addition, metabolites M4, M5, and M10 were other metabolites in rat plasma that had peak areas larger than 10% that of M0; M2-1 and M4 were the other primary metabolites in dog. No other primary metabolites were found in monkey and human (Table 2 ). These findings showed that after oral administration of flumatinib, the predominant metabolites were the products of amide hydrolysis (M3 and M4), and the metabolic profiles in plasma between these four species were qualitatively similar. Comparison with plasma from rats, dogs, and monkeys revealed no obviously exclusive metabolite in human plasma, and the levels of major metabolites in human plasma were not disproportionately higher than in any of the animal species used during nonclinical toxicology testing. The results of the present study could probably provide some instructional information for clinical safety assessment of drug metabolites, even though no specific guidance for the safety assessment of drug metabolites for cancer therapies has yet been developed.
In summary, this study presented a metabolite characterization of flumatinib in humans. Flumatinib was extensively metabolized after oral administration, and the major metabolic pathways observed were amide hydrolysis, demethylation, oxidation, and glucuronide conjugation. In addition, the metabolic profiles for circulating flumatinib in test species were similar to those observed for humans, suggesting that the safety evaluation using these species in a nonclinical setting was suitable. 
